Cargando…

Accuracy of the new rapid test for monitoring adalimumab levels

BACKGROUND: The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the tar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Cátia, Afonso, Joana, Lago, Paula, Arroja, Bruno, Vieira, Ana I., Dias, Claudia C., Magro, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393825/ https://www.ncbi.nlm.nih.gov/pubmed/30833984 http://dx.doi.org/10.1177/1756284819828238

Ejemplares similares

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
por: Rocha, Cátia, et al.
Publicado: (2020)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Clinical performance of an infliximab rapid quantification assay
por: Magro, Fernando, et al.
Publicado: (2017)

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays
por: Afonso, Joana, et al.
Publicado: (2017)

Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
por: Pinto-Lopes, Pedro, et al.
Publicado: (2021)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale
por: Santiago, Mafalda, et al.
Publicado: (2019)

Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence
por: Santiago, Mafalda, et al.
Publicado: (2020)

Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study
por: Santiago, Mafalda, et al.
Publicado: (2020)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Monitoring Crohn’s disease activity: endoscopy, fecal markers and computed tomography enterography
por: Lopes, Susana, et al.
Publicado: (2018)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
por: Afonso, Joana, et al.
Publicado: (2016)

Nanostructured Metal Oxide Sensors for Antibiotic Monitoring in Mineral and River Water
por: Magro, Cátia, et al.
Publicado: (2022)

Disseminated Tuberculosis Associated With Adalimumab Therapy
por: Silva, Marinha, et al.
Publicado: (2021)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn’s disease patients with anastomotic strictures
por: Lopes, Susana, et al.
Publicado: (2017)

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
por: Santiago, Mafalda, et al.
Publicado: (2022)

Accuracy of Expired BinaxNOW Rapid Antigen Tests
por: Vaeth, Mary Jane E., et al.
Publicado: (2023)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Volatile Organic Compound Monitoring during Extreme Wildfires: Assessing the Potential of Sensors Based on LbL and Sputtering Films
por: Magro, Cátia, et al.
Publicado: (2022)

Diagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy Study
por: Geyer, Rachel E, et al.
Publicado: (2022)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
por: Gómez-Arango, Catalina, et al.
Publicado: (2021)

Adalimumab for refractory peripheral ulcerative keratitis
por: Cordero-Coma, Miguel, et al.
Publicado: (2012)

The risk of disabling, surgery and reoperation in Crohn’s disease – A decision tree-based approach to prognosis
por: Dias, Cláudia Camila, et al.
Publicado: (2017)

Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis
por: Dias, Olívia Meira, et al.
Publicado: (2014)

Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?
por: Ministro, Paula, et al.
Publicado: (2021)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring
por: Wadhwa, Meenu, et al.
Publicado: (2021)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8coavc512935rni9hk3g3gjo3d